TVTX Q1 2025 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82M+97.5% YoY

Gross Profit

$77M94.3% margin

Operating Income

-$43M-52.2% margin

Net Income

-$41M-50.4% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+9.3%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$54M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$549M

Total Liabilities

$516M

Stockholders' Equity

$33M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$41M	+97.5%
Gross Profit	$77M	$40M	+93.3%
Operating Income	-$43M	-$139M	+69.4%
Net Income	-$41M	-$136M	+69.7%

Revenue Segments

Product

$76M93%

License

$6M7%